Abstract: Objective :To evaluate the efficacy of the combination therapy consisting of bronchial arterial infusion and adjuvant intravenous chemotherapy with the MVP regimen (mitomycin, vindesine and cisplatin) on intermediate or advanced non-small cell lung cancer. Methods :Seventy-nine patients with intermediate or advanced non-small cell lung cancer were divided into two groups at random. A combination therapy consisting of bronchial arterial infusion with the MVP regimen and adjuvant intravenous chemotherapy subsequent to the former with the same regimen was administered to the patients in the treatment group in contrast to intravenous chemotherapy alone with the MVP regimen in the control group, and a clinical control observation on effectiveness and adverse effects was carried out in two groups. Results : Of the 37 patients in the treatment group, the total response rate was 89.2R(33/37) compared with 47.6%(20/42) in the control group consisting of 42 patients. There was a statistically significant difference in the short term effectiveness of treatment with the MVP regimen between two variant administering approaches (P<0.01), as well as in the adverse effects of treatment, such as fever, gastrointestinal disturbance and bone marrow suppression (P<0.05). Conclusions :The combination therapy consisting of bronchial arterial infusion and adjuvant intravenous chemotherapy with the MVP regimen on intermediate or advanced non-small cell lung cancer shows more effectiveness and less adverse effect.